Report Publication Announcement • Jan 7, 2015
Report Publication Announcement
Open in ViewerOpens in native device viewer
Paris, FRANCE – January 7th, 2015 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specializing in cutting-edge medical equipment for echotherapy, today announced its financial agenda for 2015.
Financial publications will be released before market opening. This schedule is indicative and subject to change.
2014 Full-year sales Thursday January 29, 2015 2014 Full-year results Thursday March 19, 2015 2015 First-half results Thursday October 1st, 2015
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on cutting-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.
Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 23 people, 65 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com.
Theraclion is listed on Alternext Paris Eligible for the PEA-PME, a tax-exempt share savings plan for SMEs Ticker symbol: ALTHE – ISIN code: FR0010120402
Theraclion NewCap Phone: +33 (0)1 55 48 90 70 Phone: +33 (0)1 44 71 94 91 [email protected] [email protected]
David Caumartin Financial Communications & Investor Relations CEO Emmanuel Huynh / Sophie Boulila
Press relations Caroline Carmagnol / Valentine Boivin Phone: + 33 (0)1 44 54 36 63 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.